| Select reference and gene to see isolate summary |
| Author (yr) | Title | Citation | Isolate |
|---|
| Vingerhoets (2003) |
Antiviral Activity of TMC125, a Potent Next-Generation Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), against >5000 Recombinant Clinical Isolates Exhibiting a Wide Range of NNRTI Resistance |
unpublished | RT Lab : 35 |
| Andries (2004) |
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1 |
AAC | RT Lab : 6 |
| Das (2004) |
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian |
J Med Chem | RT Lab : 15 |
| Brillant (2004) |
In vitro Resistance Development for a second generation NNRTI: TMC125 |
unpublished | RT Lab : 7 |
| Vingerhoets (2004) |
Antiviral Activity of TMC125 against a Panel of Site-directed Mutants Encompassing Mutations Observed in vitro and in vivo |
unpublished | RT Lab : 4 |
| Vingerhoets (2005) |
TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments |
J Virol | RT Lab : 1 |
